The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium
@article{Rapkin2011TheCO, title={The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium}, author={Rachel B. Rapkin and Mitchell D. Creinin}, journal={Expert Opinion on Pharmacotherapy}, year={2011}, volume={12}, pages={2403 - 2410} }
Introduction: Neural tube defects are the second most common congenital anomaly in the United States, although their incidence may be decreased by periconception folic acid supplementation. A new oral contraceptive containing drospirenone and ethinyl estradiol plus levomefolate calcium was formulated to decrease the risk of neural tube defects in pregnancies conceived while taking or shortly after discontinuing this pill. Areas covered: Because of its novelty, very few studies have been…
3 Citations
Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: A pooled analysis of three studies conducted in North America and Europe
- MedicineThe European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
- 2013
E2V/DNG provides reliable contraceptive efficacy in women aged 18 to 50 years, and in the first 13 cycles of treatment, 76 to 81% of women experienced scheduled withdrawal bleeding, and 13 to 23% experienced intracyclic bleeding.
Simultaneous Quantification of Drospirenone, Ethinyl Estradiol and Levomefolate by Stability Indicating RP-HPLC Method
- Biology
- 2018
The developed and validated liquid chromatographic method is able to quantify the drospirenone, ethinyl estradiol and levomefolate in the presence of degradation products.
Optimization of HPLC Method Using Central Composite Design for the Estimation of Escitalopram and L-Methyl Folate
- Pharmaceutical Chemistry Journal
- 2022
Statistical design (Central Composite Design) was employed to develop an accurate and precise reverse phase high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of…
References
SHOWING 1-10 OF 36 REFERENCES
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
- MedicineObstetrics and gynecology
- 2005
A 24/4 regimen of drospirenone 3 mg and ethinyl estradiol 20 &mgr;g improves symptoms associated with premenstrual dysphoric disorder.
Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives
- MedicineObstetrics and gynecology
- 2007
Ethinylestradiol/drospirenone initiators and initiators of other oral contraceptives are similarly likely to experience thromboembolism.
A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
- MedicineCutis
- 2008
The COC 3-mg DRSP/20-microg EE 24/4 regimen COC is a suitable option for women with moderate acne vulgaris who require contraception.
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
- Biology, MedicineContraception
- 2000
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
- MedicineContraception
- 2007
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
- MedicineContraception
- 2005
Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
- MedicineContraception
- 2008
Treatment of Acne Using a 3-Milligram Drospirenone/20-Microgram Ethinyl Estradiol Oral Contraceptive Administered in a 24/4 Regimen: A Randomized Controlled Trial
- MedicineObstetrics and gynecology
- 2008
The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne.